Pharmaceutical composition for use in treating cognitive decline or for use in treating overweight or obesity
US-2024398775-A1 · Dec 5, 2024 · US
Pyrrole compounds
US8993598B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8993598-B2 |
| Application number | US-201314043018-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 1, 2013 |
| Priority date | Aug 27, 2008 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a compound represented by the formula: wherein A is pyridyl group having at least one substituent wherein R 1 , R 2 and R 3 are each a hydrogen atom, a halogen atom, a C 1-6 alkyl group optionally substituted by halogen or a C 1-6 alkoxy group optionally substituted by halogen, R 4 and R 6 are each a hydrogen atom, a halogen atom or a C 1-6 alkyl group optionally substituted by halogen, R 5 is a hydrogen atom, a halogen atom, a C 1-6 alkyl group optionally substituted by halogen or a C 1-6 alkoxy group optionally substituted by halogen, and R 7 is a hydrogen atom or a C 1-6 alkyl group optionally substituted by halogen or a salt thereof, or a pharmaceutical composition containing the same.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical composition comprising 1-{4-fluoro-5-(2-fluoropyridin-3-yl)-1-[(4-methylpyridin-2-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine or a salt thereof and a pharmacologically acceptable carrier. 2. A method for inhibiting acid secretion in a mammal, which comprises administering an effective amount of 1-{4-fluoro-5-(2-fluoropyridin-3-yl)-1-[(4-methylpyridin-2-yl)sulfonyl]-1H-pyrrol-3-yl}-N-methylmethanamine or a salt t…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8993598B2 cover?
- The present invention relates to a compound represented by the formula: wherein A is pyridyl group having at least one substituent wherein R 1 , R 2 and R 3 are each a hydrogen atom, a halogen atom, a C 1-6 alkyl group optionally substituted by halogen or a C 1-6 alkoxy group optionally substituted by halogen, R 4 and R 6 are each a h…
- Who is the assignee on this patent?
- Takeda Pharmaceutical
- What technology area does this patent fall under?
- Primary CPC classification A61K31/444. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).